Advertisement

Search Results

Advertisement



Your search for The A matches 33204 pages

Showing 1 - 50


prostate cancer

New ACS Prostate Cancer Report: Late-Stage Incidence Rates Continue to Increase Rapidly as Mortality Declines Slow

The American Cancer Society (ACS) has released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate cancer incidence rates have reversed from a decline of 6.4% per year during 2007 through 2014 to an...

issues in oncology

How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer

Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...

issues in oncology

Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies

Many patients from Europe and the United States have experienced the benefits of anthracyclines in the treatment of an array of cancers, including solid tumors such as breast and ovarian cancers as well as lymphoma. However, a number of these cancer survivors will experience severe chronic cardiac...

lung cancer

Kelly G. Paulson, MD, PhD, on Extensive-Stage SCLC: Tarlatamab Plus Anti–PD-L1 as Maintenance Therapy

Kelly G. Paulson, MD, PhD, of Providence Swedish Cancer Institute (Seattle, WA) and lead of the Center for Immuno-Oncology at Paul G. Allen Research Center, reviews findings from the safety and efficacy data from the phase Ib DeLLphi-303 trial. The study examined tarlatamab, a bispecific T-cell...

lung cancer

Viral Immunotherapy May Extend Survival in Advanced NSCLC After Progression on Immune Checkpoint Inhibition

Treatment with the viral immunotherapy CAN-2409 helped patients with unresectable, stage III/IV non–small cell lung cancer (NSCLC) continue on immune checkpoint inhibition longer and experience extended survival, despite initial inadequate responses to anti–PD-(L)1 therapy, according to extended...

lung cancer

Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC

Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), according to findings from a randomized phase II trial presented at the International...

leukemia

Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML

Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to target BCR-ABL1, in heavily pretreated patients with chronic myeloid leukemia (CML). 

lung cancer

Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib

Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1...

lung cancer

ctDNA May Guide Immunotherapy in Limited-Stage SCLC

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (Abstract MA11.09) demonstrated that monitoring circulating tumor DNA (ctDNA) may aid in refining and personalizing the use of consolidation immunotherapy in patients with...

lung cancer

Is IFITM3 a Driver of Immunotherapy Response in SCLC?

New research has identified interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. These findings were presented at the...

lung cancer

STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach

The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC), whether undergoing segmentectomy or lobectomy, according to findings from an analysis of the phase III JCOG0802/WJOG4607L trial...

lung cancer

Hypofractionated Radiotherapy Plus Concurrent Chemotherapy vs Conventional Radiotherapy in Phase III Trial for LS-SCLC

A reduced schedule for hypofractionated radiotherapy with concurrent chemotherapy led to numerically similar survival outcomes and a more favorable safety profile compared with a standard course of conventional fractionated radiotherapy for patients with limited-stage small cell lung cancer...

lung cancer

Tarlatamab and Anti–PD-1 Therapy as First-Line Maintenance for ES-SCLC

The DLL3-targeted bispecific T-cell engager agent tarlatamab demonstrated significant overall survival in combination with anti‒PD-L1 therapy of either atezolizumab or durvalumab as first-line maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC), according to...

lung cancer

New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC

The combination of subcutaneous amivantamab-vmjw every 4 weeks plus daily oral lazertinib led to a high response rate in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to findings from an analysis of cohort 5 of the PALOMA-2 trial presented at ...

lung cancer

Novel Targeted Agent Under Study in MTAP-Deleted NSCLC

BMS-986504, a first-in-class agent targeting MTAP, demonstrated antitumor activity in heavily pretreated patients with MTAP-deleted non–small cell lung cancer (NSCLC), according to findings from the phase I/II CA240-0007 trial presented at the International Association for the Study of Lung Cancer...

lung cancer

Overall Survival Risk for VATS vs Open Lobectomy for Early Lung Cancer

Video-assisted thoracoscopic surgery (VATS) led to a 21% reduction in the risk of death compared with open lobectomy for patients with early-stage lung cancer, in a meta-analysis of randomized trials comparing the two approaches. Results of the meta-analysis were presented at the International...

lung cancer

Lung Cancer Screening May Benefit Adults Up to Age 80 Who Are Fit for Surgery

Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...

lung cancer

No OS Benefit for Concurrent and Consolidative Durvalumab vs Consolidation Alone in Unresectable Stage III NSCLC

Treating patients who have stage III non–small cell lung cancer (NSCLC) with durvalumab concurrently with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival (OS) compared with consolidation therapy with durvalumab alone, according to research presented...

lung cancer

Adjuvant Chemoimmunotherapy for Resected Stage IB–IIIA NSCLC

Interim results from the phase III NADIM ADJUVANT trial, led by the Spanish Lung Cancer Group, suggest that adjuvant chemoimmunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non–small cell lung cancer (NSCLC) while maintaining an acceptable safety...

solid tumors

FDA Approves Kinase Inhibitor for Pediatric Patients With NF1

The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients aged 1 year and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA previously approved selumetinib capsules for...

bladder cancer

FDA Approves Gemcitabine Intravesical System for Non–Muscle-Invasive Bladder Cancer

The U.S. Food and Drug Administration (FDA) has approved the gemcitabine intravesical system (Inlexzo) for adults with bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors. The gemcitabine intravesical system is...

global cancer care
geriatric oncology

Bridging the Gap in Geriatric Oncology Education: A Global Imperative

As the global population ages, oncology faces an urgent challenge: ensuring that health-care professionals are adequately trained to address the unique complexities of cancer care for older adults. Despite the increasing prevalence of cancer in this demographic, geriatric oncology education remains ...

leukemia

Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL

Nirav N. Shah, MD, MSHP, of the Medical College of Wisconsin, presents results from a phase Ia study of bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader. The agent was tested in a heavily pretreated population of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and...

palliative care
pain management

Overcoming the Challenges of Safely Using Opioids to Treat Patients With Chronic Cancer-Related Pain

Research has shown that pain is among the most commonly experienced and feared aspects of a cancer diagnosis.1 It’s easy to understand why. In fact, cancer-related pain is so ubiquitous, between 20% and 50% of patients with early-stage cancer will experience pain,2 and up to 90% of patients with...

Jeffrey A. Drebin, MD, PhD, Named Chief Physician Executive of Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) recently announced that Jeffrey A. Drebin, MD, PhD, has been named Chief Physician Executive. A renowned surgeon-scientist, Dr. Drebin previously served as Chair of the Department of Surgery and brings decades of leadership and clinical experience...

lung cancer

DLL3-Targeted Antibody-Drug Conjugate in Relapsed SCLC

A first-in-human phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate, demonstrated manageable safety and early signs of antitumor activity in patients with relapsed small cell lung cancer (SCLC). The results were presented at the International...

‘A Playbook for Best Practices’: ASCO and COA Release Updated Oncology Medical Home Standards

ASCO and the Community Oncology Alliance (COA) have released updated standards for its Oncology Medical Home (OMH) certification program, which were initially codified and published in 2021.1 The 2021 systematic literature review focused on the topics of OMH model of care, clinical pathways, and...

lung cancer

Previously Treated ES-SCLC: I-DXd Demonstrates High Response Rate

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody-drug conjugate, according to data presented at the International Association for the Study of Lung Cancer...

lung cancer
immunotherapy

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...

multiple myeloma

The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma

The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when used in patients with relapsed or refractory multiple myeloma after four or more prior lines of...

multiple myeloma

Do the Results From CARTITUDE-1 Represent a Cure for Patients With Multiple Myeloma? We Need Longer Follow-Up to Know for Sure

The results of the CARTITUDE-1 clinical trial demonstrate outstanding and unprecedented long-term efficacy with ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory multiple myeloma.1 (See the July 2025 issue of The ...

lung cancer

Aumolertinib Plus Chemotherapy Improves PFS in NSCLC With EGFR and Concomitant Tumor Suppressor Genes

New results from the phase III ACROSS 2 trial demonstrated that aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), combined with platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib monotherapy in patients with...

hematologic malignancies

Is Cure Finally Achievable in Multiple Myeloma?

After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...

Radiation Oncology Leaders Name 2025 Fellows of the American Society for Radiation Oncology

The American Society for Radiation Oncology (ASTRO) selected 43 members to receive the ASTRO Fellow (FASTRO) designation this year. This prestigious honor recognizes ASTRO members’ outstanding achievements and contributions to the Society, cancer research, education, patient care, and the...

issues in oncology

Experts Share Their Perspectives on Navigating Opioid-Induced Constipation in Oncology

Constipation, a frequent and distressing side effect of cancer treatment, remains underdiagnosed and undertreated—particularly when driven by opioids. Opioid-induced constipation is distinct from functional constipation and requires tailored approaches to assessment and management. During a...

issues in oncology

Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research

The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...

prostate cancer

PARP Inhibition Plus Abiraterone Shows Benefit in HRR-Altered Metastatic Castration-Sensitive Prostate Cancer

Use of the PARP inhibitor niraparib in combination with the androgen biosynthesis inhibitor abiraterone acetate and the corticosteroid prednisone reduced the risk of disease progression, both radiographic and symptomatic, in patients with metastatic castration-sensitive prostate cancer harboring...

lung cancer

Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC

Treatment with the next-generation ROS1 tyrosine kinase inhibitor (TKI) zidesamtinib led to antitumor activity in patients with ROS1-positive non‒small cell lung cancer (NSCLC) who had experienced disease progression on prior TKI treatments. These findings from the phase I/II ARROS-1 trial were...

lung cancer

Izalontamab Brengitecan Plus Osimertinib Shows Activity in First-Line EGFR-Mutant NSCLC

The novel antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren, BL-B01D1) in combination with osimertinib induced a response in all patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR-sensitizing mutations treated with the combination in ...

lung cancer

Novel ADC Shows Promising Efficacy in Previously Treated EGFR-Mutated NSCLC

The first-in-class EGFR × HER3 bispecific antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren; BL-B01D1) demonstrated promising efficacy results plus a manageable safety profile in the treatment of patients with previously treated EGFR-mutated non–small cell lung cancer...

issues in oncology

FDA’s OCE Invites External Research Questions to Advance Science, Benefit Patients

The U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) invites academic and patient advocate researchers to propose research questions for Project Collaborate, a unique crowdsourcing initiative running through September 26. This represents a rare opportunity to leverage...

lung cancer

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase III E4512 trial presented at the...

prostate cancer

Urine-Based Biomarker Panel for the Detection of Prostate Cancer

A novel, urine-based, three-biomarker panel demonstrated significant accuracy and promising sensitivity and specificity for the detection of prostate cancers during development and validation testing, according to findings published in eBioMedicine.   “This new biomarker panel offers a promising,...

lung cancer

EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS

A new analysis from the COMPEL trial showed that patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who experienced non–central nervous system (CNS) disease progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based...

lung cancer

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

An analysis from the phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non–small cell lung cancer (NSCLC), including those with stage III N2 disease. These results were presented at the...

leukemia

All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia

As reported in the Journal of Clinical Oncology by Platzbecker et al, the European intergroup phase III APOLLO trial showed that an all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA-ATO)–based regimen was associated with improved event-free survival vs a standard ATRA plus...

issues in oncology

GLP-1 RAs and Cancer Risk in Adults With Overweight/Obesity

In a retrospective study reported in JAMA Oncology, Dai et al found that use of GLP-1 receptor agonists (GLP-1 RAs) for weight loss in adults with overweight/obesity was associated with an overall reduction in risk of cancer. As stated by the investigators, “…GLP-1 RAs… are widely prescribed for...

global cancer care

A Year of Global Progress Against Cancer—and Persistent Challenges

Despite data from the latest edition of The Cancer Atlas showing that nearly half of cancer mortality worldwide is attributed to modifiable risk factors, cancer incidence and mortality rates continue to soar.1 Globally, approximately 19 million new cases of cancer, excluding nonmelanoma skin...

genomics/genetics

Inherited Variants in 16 Genes May Double the Risk of Multiple Primary Cancers

Individuals carrying a rare pathogenic variant in one of 16 cancer-associated genes were 1.9 times more likely to develop a single cancer and 2.6 times more likely to develop multiple primary cancers, according to the results of a genetic association study published in JAMA Oncology.  These...

hematologic malignancies

Can a Common Anti-inflammatory Drug Help to Control Progression of Clonal Hematopoiesis?

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published by Mohammadnia et al in JACC ...

Advertisement

Advertisement




Advertisement